PL365705A1 - Sposób - Google Patents

Sposób

Info

Publication number
PL365705A1
PL365705A1 PL01365705A PL36570501A PL365705A1 PL 365705 A1 PL365705 A1 PL 365705A1 PL 01365705 A PL01365705 A PL 01365705A PL 36570501 A PL36570501 A PL 36570501A PL 365705 A1 PL365705 A1 PL 365705A1
Authority
PL
Poland
Prior art keywords
compounds
ammonium
azasteroids
steriods
hydrogenation
Prior art date
Application number
PL01365705A
Other languages
English (en)
Other versions
PL206539B1 (pl
Inventor
Roman Davis
Alan Millar
Jeffrey Thomas Sterbenz
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL365705A1 publication Critical patent/PL365705A1/pl
Publication of PL206539B1 publication Critical patent/PL206539B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL365705A 2000-11-03 2001-11-02 Sposób uwodorniania 4-azaandrosten-3-onów i zastosowanie tego sposobu do wytwarzania inhibitorów 5α-reduktazy PL206539B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026876.3A GB0026876D0 (en) 2000-11-03 2000-11-03 Process
PCT/US2001/048173 WO2002046207A2 (en) 2000-11-03 2001-11-02 Process

Publications (2)

Publication Number Publication Date
PL365705A1 true PL365705A1 (pl) 2005-01-10
PL206539B1 PL206539B1 (pl) 2010-08-31

Family

ID=9902484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL365705A PL206539B1 (pl) 2000-11-03 2001-11-02 Sposób uwodorniania 4-azaandrosten-3-onów i zastosowanie tego sposobu do wytwarzania inhibitorów 5α-reduktazy

Country Status (23)

Country Link
US (1) US6794508B2 (pl)
EP (1) EP1335930B1 (pl)
JP (1) JP4257117B2 (pl)
KR (1) KR100821018B1 (pl)
CN (1) CN1313480C (pl)
AT (1) ATE279429T1 (pl)
AU (2) AU2002241624B2 (pl)
BR (1) BR0115089A (pl)
CA (1) CA2427709A1 (pl)
DE (1) DE60106482T2 (pl)
DK (1) DK1335930T3 (pl)
ES (1) ES2230383T3 (pl)
GB (1) GB0026876D0 (pl)
HU (1) HUP0303907A3 (pl)
IL (2) IL155078A0 (pl)
MX (1) MXPA03003925A (pl)
NO (1) NO325180B1 (pl)
NZ (1) NZ525168A (pl)
PL (1) PL206539B1 (pl)
PT (1) PT1335930E (pl)
SI (1) SI1335930T1 (pl)
WO (1) WO2002046207A2 (pl)
ZA (1) ZA200302560B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503193B1 (ko) * 2002-08-19 2005-07-25 한미약품 주식회사 3-옥소-4-아자-5α-안드로스탄 화합물의 선택적인 제조방법
WO2005075497A1 (en) * 2004-01-07 2005-08-18 Ranbaxy Laboratories Limited PROCESS FOR THE PREPARATION OF 17ß-SUBSTITUTED-3-OXO-4-AZA-5ALPHA-ANDROSTANE DERIVATIVES
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α-还原酶抑制活性的甾体化合物及其制备方法
AR070313A1 (es) * 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
HU230730B1 (hu) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059097A (zh) * 2011-10-20 2013-04-24 连云港润众制药有限公司 一种度他雄胺中间体的制备方法
CN103254268A (zh) * 2013-05-16 2013-08-21 寿光市富康化学工业有限公司 一种制备度他雄胺的工艺
CN104231033B (zh) * 2014-09-17 2016-08-24 广东众生药业股份有限公司 一种度他雄胺的制备方法
CN108051513B (zh) * 2017-11-27 2020-09-29 重庆华邦制药有限公司 Hplc法分离测定度他雄胺起始原料sm2及其相关杂质的方法
CN109438549B (zh) * 2018-12-13 2022-01-04 湖北葛店人福药业有限责任公司 一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB2264494A (en) * 1992-02-25 1993-09-01 Merck & Co Inc 17b-n-monosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-1-en-3-one testosterone-5-alpha reductase inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones

Also Published As

Publication number Publication date
DK1335930T3 (da) 2005-02-14
IL155078A0 (en) 2003-10-31
CN1473165A (zh) 2004-02-04
EP1335930B1 (en) 2004-10-13
MXPA03003925A (es) 2003-08-19
NO325180B1 (no) 2008-02-11
DE60106482T2 (de) 2005-10-13
JP2004515505A (ja) 2004-05-27
CA2427709A1 (en) 2002-06-13
NO20031995L (no) 2003-05-02
IL155078A (en) 2009-06-15
AU4162402A (en) 2002-06-18
HK1058799A1 (en) 2004-06-04
KR100821018B1 (ko) 2008-04-08
CN1313480C (zh) 2007-05-02
AU2002241624B2 (en) 2004-10-28
PL206539B1 (pl) 2010-08-31
US20040049042A1 (en) 2004-03-11
ATE279429T1 (de) 2004-10-15
GB0026876D0 (en) 2000-12-20
WO2002046207A3 (en) 2003-03-20
HUP0303907A2 (hu) 2004-03-01
BR0115089A (pt) 2003-10-07
ZA200302560B (en) 2004-04-01
SI1335930T1 (en) 2005-04-30
EP1335930A2 (en) 2003-08-20
NO20031995D0 (no) 2003-05-02
WO2002046207A2 (en) 2002-06-13
NZ525168A (en) 2005-03-24
KR20030081326A (ko) 2003-10-17
ES2230383T3 (es) 2005-05-01
US6794508B2 (en) 2004-09-21
PT1335930E (pt) 2005-01-31
HUP0303907A3 (en) 2012-09-28
DE60106482D1 (de) 2004-11-18
JP4257117B2 (ja) 2009-04-22

Similar Documents

Publication Publication Date Title
BRPI0113670B8 (pt) composição farmacêutica e método para tratar hipogonadismo
DE69726577D1 (en) Kristallin form i von clarithromycin
AU4162402A (en) Process
MY131522A (en) PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
DE69828958D1 (de) Arzneiformulierungen zur hormonersatztherapie zur topischen anwendung auf der haut
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
NZ504423A (en) Composition having enhanced penetration capabilities and irritation reducing systems
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
DE60203013D1 (de) 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe
IL165988A0 (en) Process for the preparation of fibrinogen
GB0216002D0 (en) Process and composition
IL133004A0 (en) Pharmaceutical compositions comprising an aldose inhibitor and an ace inhibitor
SI1347764T1 (sl) Gelni sestavek na alkoholni osnovi za zdravljenje hipogonadizma s trans-skrotalno aplikacijo
SE1212311T3 (pl)
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
PT1165595E (pt) Derivados de acidos biliares especificos do figado provenientes do antagonista do glicocorticoide ru486
AU2002227970A1 (en) Method for producing cis-2-tert-butylcyclohexanol
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
AU2002347973A1 (en) Novel tibolone formulations
AU4127300A (en) Use of cellulose microfibrils in fermented milk compositions
AU2002215996A1 (en) Phenanthridine derivatives and antitumoral medicaments containing phenanthridine
GB957541A (en) 5ª‡-steroids
AU6684500A (en) Novel c-19-halogen-substituted steroids of the androst-9(11)-ene-series, methodsfor the production and use thereof

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20121102